Market news

BOSTON, September 29, 2026--Sware, Inc., the company behind the Res_Q, the AI-powered validation platform, and provider of GxP compliance solutions, today announced the appointment of Mark Hill to its Board of Directors.

On September 16, Gilead Sciences, Inc. (NASDAQ:GILD) expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to cover an investigational once-yearly formulation for HIV pre-exposure prophylaxis (PrEP). Covering 120 high-incidence, lower-income countries, the expanded framework aims to accelerate manufacturing readiness and technology transfer during the ongoing Phase 3 PURPOSE 365 study. Following […]

At first glance, Gilead Sciences, Inc. (NASDAQ:GILD) and Intuitive Surgical, Inc. (NASDAQ:ISRG) don’t make for the most obvious comparison. One sells medicines led by a massive HIV franchise, while the other has built its business around robotic surgery. Yet both have given investors a similar reason to pay attention this year, which is that growth […]

Gilead Sciences (GILD) has put fresh numbers on the table, raising its 2026 sales outlook and lifting its quarterly dividend by 3.8%, a combination that tends to grab investor attention. That guidance change is landing in a stock that already has momentum behind it, with a 90 day share price return of 19.46% and a year to date move of 24.12%. Over the longer haul, Gilead Sciences has delivered a 37.33% 1 year total shareholder return and triple digit total shareholder returns over 3 and 5...

Gilead Sciences, Inc. (NASDAQ:GILD) and Abbott Laboratories (NYSE:ABT) both return cash to shareholders through dividends, but the businesses supporting those payouts look very different. Gilead is currently growing faster, powered by an HIV franchise that continues to gain momentum, while Abbott is offering considerably more diversification across medical devices, diagnostics, nutrition and established pharmaceuticals, as […]

Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) offer investors two very different versions of pharmaceutical growth. Gilead is expanding faster, powered by an HIV franchise that continues to gain momentum, while Johnson & Johnson isn’t growing as quickly, but its portfolio stretches across pharmaceuticals and MedTech, giving it more ways to absorb weakness […]

Pfizer Inc. (NYSE:PFE) and Gilead Sciences, Inc. (NASDAQ:GILD) present investors with two very different forms of concentration risk. Pfizer needs newer medicines and its pipeline to offset revenue that will increasingly face generic and biosimilar competition, while Gilead has the opposite problem, where its biggest franchise is performing extremely well, but HIV accounts for roughly […]

Gilead Sciences (GILD) closed the most recent trading day at $152.67, moving +1.4% from the previous trading session.

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.6% on an annualized basis producing an average annual return of 16.24%. Currently, Gilead Sciences has a market capitalization of

Gilead Sciences (NasdaqGS:GILD) expanded its royalty-free voluntary licensing of once-yearly lenacapavir for HIV prevention to 120 high-incidence countries. The biopharma group signed a regional agreement with the Pan American Health Organization to widen access to twice-yearly lenacapavir across Latin America and the Caribbean. The PAHO partnership creates a direct pathway for 14 additional countries in the region to obtain lenacapavir for HIV prevention programs. Gilead's broader licensing...

Gilead Sciences, Inc. (NASDAQ:GILD) has reached an agreement with the Pan American Health Organization (PAHO) to expand access to its twice-yearly HIV-prevention drug lenacapavir across Latin America and the Caribbean. The agreement creates a regional procurement pathway through PAHO for 14 countries, including Brazil, Mexico, Argentina, Colombia and Peru, that were outside Gilead’s existing voluntary […]

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.

FOSTER CITY, Calif., September 15, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. Through PAHO’s Regional Revolving Funds, the agreement establishes a coordinated regional pathway to expand access to long-acting HIV prevention and support country-led eff

This article first appeared on GuruFocus. Gilead Sciences Inc (NASDAQ:GILD) recently announced a total dividend of $0.82 per share, with the ex-dividend date set for 2026-09-15. This upcoming distribution includes a $0.82 per share cash dividend payable on 2026-09-29.

On August 13, a federal appeals court ruled in favor of Gilead Sciences, Inc. (NASDAQ:GILD), upholding a preliminary injunction that bars the defendants from importing or facilitating the sale of foreign-market Gilead-branded medications in the US. The US Court of Appeals for the Fourth Circuit found that the differences between Gilead’s HIV medication for the […]

Gilead Sciences (NASDAQ:GILD) CFO Andy Dickinson told attendees at the Cantor Global Healthcare Conference that the company sees continued growth opportunities across its HIV prevention and treatment businesses, while advancing programs in inflammation, oncology and cell therapy. Dickinson said the

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined the company’s priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritizat

The new research centre is part of Gilead's strategy to advance US research, development and manufacturing through 2030.

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.64, denoting a -2.88% move from the preceding trading day.

Gilead Sciences, Inc. (NASDAQ:GILD) has added another treatment to its HIV portfolio with the FDA approval of Bixlenvo, a once-daily pill for adults whose infection is already suppressed to very low levels. The combination brings together bictegravir, a key component of Gilead’s (NASDAQ:GILD) blockbuster Biktarvy, and lenacapavir, the foundation of the company’s longer-term HIV strategy. […]

Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.

Gilead Sciences recently secured U.S. FDA approval for Bixlenvo, a once-daily single tablet regimen for virologically suppressed adults with HIV on complex regimens, and European Commission approval for Trodelvy plus Keytruda as a first-line treatment for certain PD-L1–positive metastatic triple-negative breast cancer patients. These back-to-back approvals broaden Gilead’s reach in HIV and oncology by addressing hard-to-treat, heavily pretreated populations with simplified or first-in-class...

Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out. Here is what that risk actually means for income investors counting on the check.

Mutual Fund Report for ETGLX

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.

Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.

Gilead Sciences (GILD) has been granted U.S. FDA approval for its once-daily antiviral pill, Bixlenvo as the smallest single-tablet HIV regimen. Read more here.